“LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT”. Voprosy onkologii 65, no. 3 (March 1, 2019): 386–392. Accessed October 14, 2026. https://voprosyonkologii.ru/index.php/journal/article/view/974.